Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

The Boston Scientiofic Acurate Neo TAVR valve did not meet non-inferiority to the Sapien 3 valve in patients with severe aortic stenosis. #TAVR #TCT2019
News | Heart Valve Technology | October 02, 2019

October 2, 2019 – The first randomized trial to compare the safety and efficacy of the new Boston Scientific Acurate...

The Portico FDA investigational device exemption (IDE) study found that 30-day safety and one-year effectiveness outcomes of a novel self-expanding transcatheter aortic valve replacement (TAVR) system for patients with severe aortic stenosis (AS) at high or extreme-risk for surgery was noninferior to contemporary FDA-approved TAVR systems. #TAVR #TCT2019
News | Heart Valve Technology | October 02, 2019

October 2, 2019 – The Abbott Portico FDA investigational device exemption (IDE) study found that 30-day safety and...

Three-Month DAPT Post-PCI Demonstrates Low Adverse Event Rate in High-Bleeding Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 30, 2019

September 30, 2019 – Data from the EVOLVE Short DAPT study found that shortened three-month...

Positive Safety, Efficacy Data Reported on AccuCinch Heart Failure Device
News | Heart Failure | September 27, 2019

September 27, 2019 — Ancora Heart Inc. announced results from an interim analysis of...

Brilinta Monotherapy Reduces Clinically Relevant Bleeding Risk Post-PCI in High-Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 26, 2019

September 26, 2019 — New data from the Phase IV independent TWILIGHT trial showed...

Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival
News | Cath Lab | September 25, 2019

September 25, 2019 — Ten-year survival rates are similar for...

Videos | Hemodynamic Support Devices | September 22, 2019

There was a 77 percent increase in survival in cardiogenic shock patients treated using a new protocol in the...

Early ICD Use Prolongs Survival After Coronary Stenting
News | Implantable Cardioverter Defibrillator (ICD) | September 18, 2019

September 18, 2019 — Early use of an...

Rapid Diagnosis Protocol for Chest Pain Does Not Improve Outcomes
News | Blood Testing | September 18, 2019

September 18, 2019 — Discharge of patients with suspected acute coronary syndromes under a 0- and 1-hour...

Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Ablation Systems | September 17, 2019

September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can...

Corvia Medical and physIQ Partner in Global Phase 3 Heart Failure Device Clinical Trial

The REDUCE LAP HF-II study will combine Corvia Medical's InterAtrial Shunt Device (IASD), pictured here, with physIQ's continuous monitoring platform to evaluate the device's efficacy in patients with heart failure. Image courtesy of Corvia Medical.

News | Heart Failure | September 12, 2019

September 12, 2019 — Corvia Medical has sponsored and is actively enrolling patients in a...

Overlay Init